



Final Appraisal Recommendation
Advice No: 0421 – March 2021

Lurasidone (Latuda®) 18.5 mg, 37 mg, 74 mg film-coated tablets

Submission by Sunovion Pharmaceuticals Europe Ltd

Recommendation of AWMSG

Lurasidone (Latuda®) is recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults and adolescents aged 13 years and over.

Additional note(s):

- The above advice incorporates and replaces the AWMSG recommendation for lurasidone (Latuda®) for the treatment of schizophrenia in adults aged 18 years and over (advice number 0115, originally published February 2015).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference numbers 4394 and 1142), which includes the All Wales Therapeutics and Toxicology Centre (AWTTC) assessment, AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0421:
Lurasidone (Latuda®) 18.5 mg, 37 mg and 74 mg film-coated tablets March 2021